+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Targeted therapies to treat non-AIDS-defining cancers in patients with HIV on HAART therapy: treatment considerations and research outlook



Targeted therapies to treat non-AIDS-defining cancers in patients with HIV on HAART therapy: treatment considerations and research outlook



Current Opinion in Oncology 21(5): 445-454



Highly active antiretroviral therapy has led to a dramatic improvement in the prognosis of patients diagnosed with HIV and AIDS. This includes a significant decline in the rates of AIDS-related cancers, including Kaposi's sarcoma and non-Hodgkin's lymphoma. Unfortunately, rates of non-AIDS-defining cancers are on the rise, and now exceed the rates of AIDS-related cancers in patients with HIV. Treating non-AIDS-defining cancers in patients who are on highly active antiretroviral therapy is an open and complicated clinical question. Newer targeted therapies are now available to treat cancers which were historically refractory to traditional cytotoxic chemotherapy. Highly active antiretroviral therapy agents are notorious for causing drug-drug interactions. The co-administration of targeted chemotherapies with highly active antiretroviral therapy could well impede the efficacy or increase the toxicity of these targeted therapies. Unfortunately little is known about possible drug-drug interactions because HIV patients are typically excluded from clinical trials. We highlight what is known about how and why highly active antiretroviral therapy agents can affect drug metabolism. We then present the clinical and pharmacological data for nine recently approved targeted therapies - imatinib, dasatinib, nilotinib, erlotinib, sunitinib, lapatinib, bortezomib, sorafenib, and temsirolimus. We conclude with considerations on how to use these new agents to treat non-AIDS-defining cancers, and discuss a future research agenda to better understand and predict potential highly active antiretroviral therapy-targeted therapy interactions.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 056119216

Download citation: RISBibTeXText

PMID: 19606034

DOI: 10.1097/cco.0b013e32832f3e04


Related references

Assessing the impact of HAART on the incidence of defining and non-defining AIDS cancers among patients with HIV/AIDS: a systematic review. Journal of Infection and Public Health 8(1): 1-10, 2015

Features of AIDS and AIDS defining diseases during the highly active antiretroviral therapy (HAART) era, compared with the pre-HAART period: a case-control study. Sexually Transmitted Infections 76(2): 145-B-146, 2000

Short Communication: HIV RNA Levels Predict AIDS-Defining and Non-AIDS-Defining Cancers After Antiretroviral Therapy Initiation Among HIV-Infected Adults. Aids Research and Human Retroviruses 31(5): 514-518, 2015

Incidence of AIDS-defining cancers and virus-related and non-virus-related non-AIDS-defining cancers among HIV-infected patients compared with the general population in a large health district of Northern Italy, 1999-2009. HIV Medicine 14(8): 481-490, 2014

Incidence and risk factors of non AIDS-defining as compared with AIDS-defining infections and cancers in a cohort of HIV-infected patients initiating a protease inhibitor -containing regimen. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 41: 320, 2001

Trends and predictors of non-AIDS-defining cancers in men and women with HIV infection: a single-institution retrospective study before and after the introduction of HAART. Journal of Acquired Immune Deficiency Syndromes 62(4): 414-420, 2013

Effects of the introduction of highly active antiretroviral therapy (HAART) on the temporal trend of diagnosis of AIDS and AIDS-defining disorders. Le Infezioni in Medicina 8(3): 134-138, 2000

Antiretroviral combination therapies and AIDS-defining cancers. Journal of Acquired Immune Deficiency Syndromes 24(1): 84-86, 2000

AIDS-defining diseases and HIV-related immunodeficiency in patients developing AIDS during the HAART era What is changing?. International Journal of Antimicrobial Agents 19(Suppl. 1): S9, 2002

Ocular manifestations of AIDS: new considerations for patients using highly active anti-retroviral therapy (HAART). Optometry 75(10): 624-628, 2004

HIV and Cancer: An Overview of AIDS-Defining and Non-AIDS-Defining Cancers in Patients With HIV. Clinical Journal of Oncology Nursing 23(3): 327-331, 2019

Future treatment for non-AIDS-defining cancers in HIV-infected patients. HIV Therapy 3(4): 311-314, 2009

Trends in the incidence of AIDS-defining and non-AIDS-defining cancers in people living with AIDS: a population-based study from São Paulo, Brazil. International Journal of Std and Aids 28(12): 1190-1198, 2017

Burden of non-AIDS-defining and non-virus-related cancers among HIV-infected patients in the combined antiretroviral therapy era. Aids Research and Human Retroviruses 29(8): 1097-1104, 2013

Non-AIDS-Defining Malignancies in Patients with HIV in the HAART Era. Current Infectious Disease Reports 12(1): 46-55, 2010